Lotus Pharmaceuticals Stock Net Income
| LTUS Stock | USD 0 0.0003 8.57% |
As of the 11th of February 2026, Lotus Pharmaceuticals secures the Mean Deviation of 6.56, downside deviation of 26.13, and Risk Adjusted Performance of 0.0355. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lotus Pharmaceuticals, as well as the relationship between them. Please verify Lotus Pharmaceuticals information ratio and downside variance to decide if Lotus Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 0.0038 per share. As Lotus Pharmaceuticals appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.
Lotus Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lotus Pharmaceuticals' valuation are provided below:Lotus Pharmaceuticals does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Lotus |
Lotus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lotus Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lotus Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Lotus Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Lotus Pharmaceuticals or generate 0.0% return on investment in Lotus Pharmaceuticals over 90 days. Lotus Pharmaceuticals is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Lotus Pharmaceuticals, Inc. does not have significant operations More
Lotus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lotus Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lotus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 26.13 | |||
| Information Ratio | 0.0267 | |||
| Maximum Drawdown | 105.64 | |||
| Value At Risk | (23.08) | |||
| Potential Upside | 26.67 |
Lotus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lotus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lotus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Lotus Pharmaceuticals historical prices to predict the future Lotus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0355 | |||
| Jensen Alpha | 0.3491 | |||
| Total Risk Alpha | (1.15) | |||
| Sortino Ratio | 0.0165 | |||
| Treynor Ratio | 0.2584 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lotus Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lotus Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0355 | |||
| Market Risk Adjusted Performance | 0.2684 | |||
| Mean Deviation | 6.56 | |||
| Semi Deviation | 9.76 | |||
| Downside Deviation | 26.13 | |||
| Coefficient Of Variation | 3084.85 | |||
| Standard Deviation | 16.14 | |||
| Variance | 260.57 | |||
| Information Ratio | 0.0267 | |||
| Jensen Alpha | 0.3491 | |||
| Total Risk Alpha | (1.15) | |||
| Sortino Ratio | 0.0165 | |||
| Treynor Ratio | 0.2584 | |||
| Maximum Drawdown | 105.64 | |||
| Value At Risk | (23.08) | |||
| Potential Upside | 26.67 | |||
| Downside Variance | 682.53 | |||
| Semi Variance | 95.26 | |||
| Expected Short fall | (27.60) | |||
| Skewness | 1.97 | |||
| Kurtosis | 10.62 |
Lotus Pharmaceuticals Backtested Returns
Lotus Pharmaceuticals is out of control given 3 months investment horizon. Lotus Pharmaceuticals has Sharpe Ratio of 0.0783, which conveys that the firm had a 0.0783 % return per unit of risk over the last 3 months. We are able to break down and analyze data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.24% are justified by taking the suggested risk. Use Lotus Pharmaceuticals Risk Adjusted Performance of 0.0355, mean deviation of 6.56, and Downside Deviation of 26.13 to evaluate company specific risk that cannot be diversified away. Lotus Pharmaceuticals holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.99, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lotus Pharmaceuticals will likely underperform. Use Lotus Pharmaceuticals total risk alpha, downside variance, as well as the relationship between the Downside Variance and rate of daily change , to analyze future returns on Lotus Pharmaceuticals.
Auto-correlation | 0.08 |
Virtually no predictability
Lotus Pharmaceuticals has virtually no predictability. Overlapping area represents the amount of predictability between Lotus Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lotus Pharmaceuticals price movement. The serial correlation of 0.08 indicates that barely 8.0% of current Lotus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Lotus Pharmaceuticals reported net income of 14.42 M. This is 98.87% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 97.47% higher than that of the company.
Lotus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lotus Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Lotus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceuticals by comparing valuation metrics of similar companies.Lotus Pharmaceuticals is currently under evaluation in net income category among its peers.
Lotus Fundamentals
| Return On Equity | 0.0182 | |||
| Return On Asset | 0.0456 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 762.17 K | |||
| Shares Outstanding | 27.82 M | |||
| Price To Earning | 0.18 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 72.7 M | |||
| Gross Profit | 39.78 M | |||
| EBITDA | 10.31 M | |||
| Net Income | 14.42 M | |||
| Cash And Equivalents | 158.91 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5.24 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 0.53 X | |||
| Book Value Per Share | 3.58 X | |||
| Cash Flow From Operations | 26.78 M | |||
| Earnings Per Share | 0.06 X | |||
| Number Of Employees | 233 | |||
| Beta | 0.51 | |||
| Market Capitalization | 834.49 K | |||
| Total Asset | 103.18 M | |||
| Retained Earnings | 65 M | |||
| Working Capital | (6 M) | |||
| Current Asset | 8 M | |||
| Current Liabilities | 14 M | |||
| Net Asset | 103.18 M |
About Lotus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lotus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lotus Pink Sheet Analysis
When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.